Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24236941 | 0.83 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL18519546 | 0.77 | ADORA3 (0.44) | ADORA3BRD4 | |
| SCHEMBL21137626 | 0.72 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL23476796 | 0.72 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL18510357 | 0.72 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL21137236 | 0.70 | ADORA3 (0.40) | ADORA3BRD4 | |
| SCHEMBL17674862 | 0.70 | GRIN2D (0.41) | ADORA3BRD4 | |
| SCHEMBL21539430 | 0.69 | ADORA3 (0.42) | ADORA3BRD4 | |
| SCHEMBL22326718 | 0.68 | ADORA3 (0.39) | ADORA3BRD4 | |
| SCHEMBL24859515 | 0.64 | BRD4 (0.41) | ADORA3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA3 122/4885BRD4 1650/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA3 117/4885BRD4 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.